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Aldose reductase expression is induced by hyperglycemia in supported by the familial clustering of nephropathy in
diabetic nephropathy. those patients with type 1 or type 2 diabetes [6, 7].
Background. Despite good metabolic control, many patients Recent studies have suggested that genetic variation in
with type 1 diabetes still develop nephropathy, implicating a
the aldose reductase (ALR2) gene may contribute to therole for genetic factors. Recent studies examining the regula-
genetic susceptibility to diabetic nephropathy [8–12]. Al-tory region of the aldose reductase (ALR2) gene, the rate-
limiting enzyme of the polyol pathway, support its role as a dose reductase is the first and rate-limiting enzyme of the
candidate gene for nephropathy. Here we report the quantita- polyol pathway and converts glucose to sorbitol in a
tion of ALR2, together with sorbitol dehydrogenase mRNA nicotinamide adenine dinucleotide phosphate (NADPH)-
in the peripheral blood mononuclear cells (PBMCs) of type 1
dependent reaction. Sorbitol is metabolized to fructosediabetic patients with (N  29) and without nephropathy (N 
by sorbitol dehydrogenase (SORD) using NAD as a co-11) following stimulation with high levels of d-glucose.
factor [13–16]. Excessive flux through the polyol pathwayMethods. PBMCs from patients and normal controls were
cultured for five days with phytohemagglutinin in either normo- caused by hyperglycemia is likely to lead to a number of
glycemia (11 mmol/L d-glucose) or supplemented with 10 mmol/L metabolic and vascular defects that ultimately may give
d-glucose (moderate hyperglyemia) or 20 mmol/L d-glucose (hy-
rise to tissue hypoxia and ischemia. Patients with diabeticperglycemia). The RNA was extracted and analyzed by ribonu-
microvascular complications have been shown to haveclease protection assay.
raised enzymatic activity of aldose reductase as well asResults. ALR2 mRNA levels were significantly elevated with
increasing d-glucose concentration (normal to hyperglycemic) an increased amount of the protein compared with those
in those patients with nephropathy (P  0.0001). In marked with no microvascular complication [17, 18]. Patients
contrast, in those without nephropathy and in the normal healthy with type 1 diabetes and nephropathy also have beencontrols, there was no change in mRNA expression. Further-
shown to have increased levels of ALR2 mRNA [19].more, those patients with nephropathy and the Z–2/X suscepti-
This increase in mRNA appears to be linked to a geneticbility genotype had the greatest increase in ALR2 mRNA
compared with those with low-risk genotypes (P  0.007). variation in the promoter region of the ALR2 gene [11].
Conclusion. These results show that patients with nephropa- Two polymorphic regions in the promoter region of
thy exhibit marked disturbances in the expression of the en- ALR2 have been identified and shown to be associatedzyme components of the polyol pathway. Ultimately this leads
with susceptibility to nephropathy in Caucasoid patientsto tissue damage and ischemia.
who have type 1 diabetes. A CA dinucleotide repeat
region designated 5ALR2 is located at approximately
2.1 kb upstream of the initiation site in close proximityThere is increasing evidence to suggest that genetic
to the osmotic response elements [20]. A second poly-factors are involved in the pathogenesis of diabetic ne-
morphism, the C(-106)T site, occurs in the basal promoterphropathy in patients with type 1 diabetes [1–3]. The
region [21]. The Z–2 5ALR2 allele, where Z is the mostincidence peaks between 15 and 20 years duration of
common allele and consists of 24 CA repeats, has beendiabetes and subsequently declines rapidly [4, 5]. This is
shown to occur with increased frequency in patients with
type 1 diabetes and nephropathy. Patients with either
type 1 or type 2 diabetes and retinopathy from a numberKey words: sorbitol dehydrogenase, gene expression, blood sugar, type
1 diabetes, ALR2 gene. of ethnic groups, including Caucasoid, Japanese, and
Chinese origin, have also been found to have an increasedReceived for publication November 28, 2000
frequency of the Z–2 allele [8–12, 20, 21].and in revised form February 14, 2001
Accepted for publication February 19, 2001 The level of mRNA expression of ALR2 has been
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Table 1. Clinical characterization of patient subgroups and normal controls
Diabetic controls
Diabetic nephropaths (uncomplicated) Normal controls
No. of subjects 29 11 10
Age years (range) 4311.3 (24–69) 46.513.4 (27–70) 35.48.4 (24–49)
Age at onset of diabetes years (range) 12.69.0 (1–36) 19.611.1 (4–42)
Duration of diabetes (range) 30.67.9 (15–43) 3110.5 (22–51)
Hemoglobin A1c (range) 9.21.6 (6.1–12.2) 8.51.5 (7.2–11.2)
Insulin dosage units 38.210.4 (24–70) 61.131.7 (20–118)
Sex male:female 12:17 4:7 7:3
Data are expressed as mean values  standard deviation together with the range (in parentheses). All patients had type 1 diabetes mellitus as defined by the
National Diabetes Data Group. The hemoglobin A1c values were not significantly different between the patient groups.
clear cells (PBMCs) of Caucasoid patients with type 1 or blots per eye; hard or soft exudates, new vessels,
diabetes and nephropathy who have the Z–2 allele [11]. or fluorescein angiographic evidence of maculopathy or
The Z–4 allele of Japanese patients with type 2 diabetes previous laser treatment for preproliferative or prolifera-
and retinopathy has been shown to confer increased gene tive retinopathy; and maculopathy or vitreous hemor-
expression in reporter assays using human retinal pig- rhage. Fundoscopy was performed by both a diabetolo-
ment epithelial cells exposed to hyperglycemia [22]. How- gist and ophthalmologist (the clinical characteristics of
ever, at the present time, nothing is known about hyper- the subjects are shown in Table 1).
glycemia-induced expression of the ALR2 and SORD Normal healthy controls (N  10). Peripheral blood
genes in the PBMCs of patients with or without nephrop- samples were obtained from 10 healthy volunteers with
athy. The expression profile of ALR2 and SORD genes no family history of type 1 or type 2 diabetes.
under hyperglycemic conditions may explain why certain
individuals with diabetes develop complications while Isolation and culturing of peripheral blood
others do not. mononuclear cells from whole blood
Here we provide compelling evidence to show that
Twenty milliliters of peripheral blood were collectedthe expression profile of the ALR2 and SORD genes
into 5% ethylenediaminetetraacetic acid (EDTA) Vacu-differs substantially between those patients with nephrop-
tainers (Becton Dickinson, Oxford, UK). The blood wasathy compared with those who remain free of microvas-
diluted 1:1 in phosphate-buffered saline (PBS), and thecular complications after 20 years of diabetes.
PBMCs were harvested following standard density gradi-
ent centrifugation. The PBMCs were washed four times
METHODS and resuspended at a concentration of 0.5  106/mL in
Study subjects RPMI 1640 (11 mmol/L d-glucose) supplemented with
penicillin/streptomycin (GIBCO GRL, Paisley, Scotland,Forty patients were recruited from the Diabetic Out-
Patient Clinic (Dr. Millward, Derriford Hospital, Ply- UK), 10% fetal calf serum (GIBCO) and l-glutamine
mouth, UK). Local ethical committee approval was ob- (Sigma Chemicals, Poole, Dorset, UK) and separated
tained. The patients were classified according to their into three flasks. The first of these was cultured for five
microvascular complications, as previously described days with phytohemagglutinin (11 mmol/L d-glucose
[8–10]. concentration within the media normoglycemia), and the
Uncomplicated patients (N  11). These patients had second was supplemented with 10 mmol/L d-glucose
type 1 diabetes for at least 20 years but remained free (moderate hyperglycemia) and the third with 20 mmol/L
of retinopathy (fewer than 5 dots or blots per fundus), d-glucose (hyperglycemia) before culture. Additional
proteinuria (negative on urine Albustix on at least three experiments using cultures of PBMCs were established
consecutive occasions over the previous 12 months), and to control for osmosity and hyperglycemia. In the first,
overt neuropathy. Overt neuropathy was defined if there
20 mmol/L mannitol were used as a supplement with thewas any clinical evidence of peripheral or autonomic
20 mmol/L d-glucose. A second, parallel culture con-neuropathy.
sisted of 20 mmol/L l-glucose being used as the supple-Nephropaths (N  29). These patients had type 1 dia-
ment with the 20 mmol/L d-glucose.betes for more than 10 years and had proteinuria (urine
Albustix positive on at least three consecutive occasions
Extraction of RNAover 12 months or three successive total urinary protein
At the end of the incubation period, the cells wereexcretion rates of greater than 0.5 g/24 h) in the absence
pelleted by centrifugation. The supernatant was removed,of hematuria or infection on midstream urine samples.
and the cells were resuspended and lyzed in RNA StatDiabetic nephropathy was always associated with reti-
nopathy. Retinopathy was defined as more than five dots 60 (Biogenesis, Poole, UK). The solution was then
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transferred to an RNase-free Eppendorf; 200 L of chlo- Systems, Cambridge, UK) for 10 to 30 seconds. The
probe was excised, immersed in 350 L of elution bufferroform were added (Sigma Chemicals), vortexed, and
centrifuged at 13,000  g for 15 minutes at 4C. The (Ambion), and then incubated overnight at 37C to ob-
tain 95% recovery.upper aqueous phase was transferred to a clean Eppen-
dorf, mixed with 500 L of isopropanol and centrifuged.
Hybridization of ribonuclease protection assay probeThe supernatant was discarded, and the pellet was
to RNA samplewashed in 75% ethanol and resuspended in 50L diethyl
pyrocarbonate (DEPC)-treated water by vortexing. The The RNA sample and the ribonuclease protection assay
(RPA) antisense probe were mixed together and precipi-approximate amount of total RNA extracted was deter-
mined using a Cecil 5500 spectrophotometer scanning tated with ethanol and ammonium acetate. The RNA mix
was pelleted by centrifugation, dissolved in 20 L of240 to 280 nm (Cecil Instruments Ltd., Nottingham, UK).
hybridization buffer (Ambion), and then centrifuged to
Preparation, amplification, and radiolabeling and collect at the bottom of the tube. The sample was then
purification of antisense RNA probes briefly incubated at 92C, vortexed, centrifuged, and then
incubated overnight at 42C. For the Rnase digestion,High-molecular-weight DNA was prepared from 10 mL
of peripheral blood using Nucleon extraction kits (Scot- 200 L of diluted RNase mix (Ambion) was then added,
and the mixture was incubated for 30 minutes at 37C,lab, Paisley, Scotland, UK). An aliquot of this DNA was
amplified using the polymerase chain reaction (PCR). after which 300 L of RNase inactivation/precipitation
solution (Ambion) was added, vortexed, and centri-Exons of ALR2 and SORD were amplified using three
separate primers for each gene. The first round amplifi- fuged. The reaction was then transferred to 20C for
at least 15 minutes. The protected fragments were sepa-cation reaction was performed in 30 L volumes con-
taining the amplimers for ALR2: sense, 5-CTG TAG rated and detected by centrifugation of the sample for
CTC CCA CAA CGA TTA CCC-3; antisense, 5-CAA 15 minutes at 4C, and the pellet was resuspended in gel
GCA GTC AAA ACT CAA CCG TTA G-3; and for loading buffer. The sample was then heated for three to
SORD: sense, 5-CAA AGC CAT CCT GGG CTG four minutes at 94C and loaded onto a 5% acrylamide
CAT GTG GG-3; antisense, 5-CTT TCC TGG CGA gel, and electrophorosed for approximately 40 minutes
CCT GAG GGC-3; 10 mmol/L dNTPs (Pharmacia Bio- to 1 hour at 200 V, transferred to filter paper (Whatman,
tech, UK), 10  buffer solution, 10 mmol/L MgC12, 1 U Maidstone, UK), and exposed to Kodak X-Omat film
Taq polymerase (HT Biotech, Mayfield, UK). The sam- at 80C overnight. The bands were analyzed using a
ples were subjected to an initial cycle of denaturation phospho-imager (Biorad, Hertfordshire, UK). An inter-
for two minutes at 96C. This was followed by 30 cycles nal control 	-actin was set up to ascertain any variations
of amplification that consisted of denaturation for 30 in the amount of RNA used in the RPA. pTRI-actin, a
seconds at 94C, annealing for 1 minute at 50C, and DNA template, was provided in the RPA kit (Ambion)
extension for 1 minute at 72C in a PTC-200 Thermal and used for the transcription of an antisense 	-actin
Cycler (MJ Research, Essex, UK). A second round of RNA probe.
amplification was then employed using the antisense am-
Statistical analysisplimer with an RNA polymerase T7 adapter and stuffer
nucleotides, ALR2: Antisense 
 T7 – 5-TAA TAC Results are expressed as means  SE. Statistical sig-
GAC TCA CTA TAG GGA GG CAA GCA GTC nificance was assessed by Student t tests after analysis of
AAA ACT CAA CCG TTA G-3; SORD: Antisense 
 variance (ANOVA) or Mann–Whitney U test. A P value
T7 – 5-TAA TAC GAC TCA CTA TAG GGA GG of 0.05 was considered to be significant.
CTT TCC TGG CGA CCT GAG GGC-3; 10 mmol/L
dNTPs, 10  buffer solution, 10 mmol/L MgCl2, 1 U Taq
RESULTSpolymerase. The samples were then subjected to DNA
Forty patients with type 1 diabetes were recruited foramplification as described previously in this article. One
the study. Twenty-nine of these had diabetic nephropa-microgram of the product was used to generate the radio-
thy (nephropaths), and 11 had remained free of micro-active RNA probes by incorporating 32P UTP (Amer-
vascular disease (absence of background retinopathy,sham Pharmacia Biotech, Amersham, Bucks, UK) using
microalbuminuria, and overt neuropathy) after 20 yearsthe MAXIscript System (Ambion, Abingdon, UK).
duration of diabetes (uncomplicated). Ten normal healthyAn equal volume of gel loading buffer (Ambion) was
controls were also studied. The clinical characteristics ofadded to the reaction and heated to 85 to 95C for 3 to
the subjects are shown in Table 1. Figure 1A shows the5 minutes and then loaded onto a 5% acrylamide/8 mol/L
expression of the housekeeping gene 	-actin mRNA inurea gel and run at approximately 100 to 200 V for 40
a patient with diabetic nephropathy. The level of 	-actinminutes to 1 hour. The gel was wrapped in SaranWrap
and exposed to Kodak X-Omat film (Scientific Imaging expression was similar between the samples of PBMCs
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Fig. 1. (A) An example of mRNA from pe-
ripheral blood mononuclear cells (PBMCs) of
a patient with diabetic nephropathy that had
been exposed to normal, moderate, and severe
hyperglycemia and hybridized to -actin in a
ribonuclease protection assay. The fold differ-
ences in 	-actin mRNA between the normal,
moderate, and severe samples were 1.2 and
1.0, respectively. (B) The same mRNA sam-
ples from the patient with nephropathy as de-
picted in (A) as well as those from an uncom-
plicated patient. In contrast to the 	-actin
results shown in (A), there was a 2.0- and
7.6-fold increase in the expression of aldose
reductase (ALR2) mRNA in PBMCs exposed
to moderate and severe hyperglycemia in the
patient with diabetic nephropathy. There was
no change in the ALR2 mRNA expression
with hyperglycemia in the uncomplicated pa-
tient.
stimulated with different concentrations of d-glucose plemented with 20 mmol/L d-glucose) in the nephro-
paths, uncomplicated, and the normal controls are shown(fold increase in the samples supplemented with d-glu-
cose was up to 1.2 compared with normal samples). This in Table 2 and Figures 2 and 3. The results are expressed
as fold increase in mRNA above the level obtained underdemonstrates that equal amounts of study RNA (10 g)
were loaded and that variations in ALR2 and SORD normal conditions. In the nephropaths, the mean fold
increase of ALR2 mRNA in moderate hyperglycemiamRNA expression were real and not caused by loading
errors. Figure 1B shows the expression of ALR2 mRNA was 1.8  0.2-fold, while in severe hyperglycemia there
was a 3.8  0.8-fold increase (P  0.0001). In markedin PBMCs in the same patient with diabetic nephropathy
as well as an uncomplicated subject stimulated with dif- contrast, in the uncomplicated group of patients as well
as the normal controls, there was no elevation of ALR2ferent concentrations of d-glucose. The fold increases of
ALR2 mRNA in the diabetic nephropath were 2.0 and mRNA expression with increasing d-glucose concentra-
tion. Indeed, in both these groups, there was a slight7.6 for the PBMCs exposed to moderate or hyperglyce-
mia, respectively. decrease (0.9  0.02 and 0.94  0.1 for moderate hyper-
glycemia, respectively, and 0.8  0.05 and 0.8  0.1 forThe mean levels of ALR2 as well as SORD mRNA
in PBMC exposed to normal, moderate (supplemented severe hyperglycemia, respectively; Table 2). The differ-
ences in response of ALR2 between the nephropaths andwith 10 mmol/L d-glucose), or severe hyperglycemia (sup-
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Table 2. Overall mean levels of ALR2 and SORD mRNA in moderate and hyperglycemic conditions in the study groups
Diabetic nephropaths Diabetic controls Normal controls
N  29 N  11 N  10
Glucose concentration ALR2 SORD ALR2 SORD ALR2 SORD
Moderate 1.80.2a 1.40.1c 0.90.02 0.90.05 0.940.1 0.940.07
Hyperglycemic 3.80.8b 2.20.3d 0.80.05 0.90.05 0.80.1 0.840.07
The results are expressed as mean values  standard error.
a vs. uncomplicated, P  0.00002, and vs. normal controls, P  0.0004
b vs. uncomplicated, P  0.0001, and vs. normal controls, P  0.001
c vs. uncomplicated, P  0.01, and vs. normal controls, P  0.001
d vs. uncomplicated, P  0.006, and vs. normal controls, P  0.005
Fig. 2. Mean fold increase of ALR2 mRNA in PBMCs from nephropaths () and uncomplicated () and normal () controls cultured under
normal and hyperglycemic conditions. Glucose concentration vs. ALR2 mRNA, P  0.00001. Moderate conditions: nephropaths vs. uncomplicated,
P  0.00002, nephropaths vs. normal controls, P  0.004. Severe conditions: nephropaths vs. uncomplicated, P  0.0001, nephropaths vs. normal
controls, P  0.001.
uncomplicated as well as the normal controls was highly 20 mmol/L mannitol, there was a reduction in the expres-
sion of ALR2 (Fig. 4). In contrast, with d-glucose alonesignificant (moderate conditions, P  0.00002 nephro-
paths vs. uncomplicated nephropaths, and P  0.004 vs. (supplemented with 20 mmol/L d-glucose), there was an
expected increase in ALR2 mRNA (Fig. 4).normal control; severe conditions, P  0.0001 nephro-
paths vs. uncomplicated; Table 2). Figure 2 shows an When the SORD mRNA was measured in the same
samples again, the nephropaths had a significant increaseexample of the increase in ALR2 mRNA of PBMCs stimu-
lated with d-glucose from a nephropath in contrast to in mRNA expression with increasing concentrations of
d-glucose (P 0.01, 1.4 0.1 and 2.2 0.3 for moderatethe lack of a response of PBMCs from an uncomplicated
patient who was treated in the same way. To determine and severe hyperglycemia, respectively; Table 2 and Fig.
3). There was a slight decrease in SORD mRNA expres-whether the increased expression of ALR2 in the nephro-
paths was specific for d-glucose the PBMCs from two sion in the uncomplicated and normal controls with in-
creasing concentration of d-glucose (Table 2 and Fig. 3).patients with nephropathy were stimulated with either
l-glucose, which competes with d-glucose for the trans- In the nephropaths, there was a significant correlation
between the increase in ALR2 mRNA expression underporter, or mannitol, an osmolyte that at high concentra-
tions can activate p38 mitogen-activated protein kinase severe hyperglycemic conditions and the Z–2/X (where
X is not Z
2) 5ALR2 susceptibility genotype (Table 3).[23]. When the tissue culture media for the PBMCs was
also supplemented with either 20 mmol/L l-glucose or In those patients with this genotype, there was an 8.4 
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Fig. 3. Mean fold increase of SORD mRNA in PBMCs from nephropaths () and uncomplicated () and normal () controls cultured under
normal and hyperglycemic conditions. Glucose concentrations vs. SORD mRNA, P  0.01. Moderate conditions: nephropaths vs. uncomplicated,
P  0.01; nephropaths vs. normal controls, P  0.03. Severe conditions: nephropaths vs. uncomplicated, P  0.006; nephropaths vs. normal controls,
P  0.005.
Fig. 4. ALR2 mRNA expression in PBMC
of patients with diabetic nephropathy. ALR2
mRNA is induced by d-glucose, but not by
mannitol or l-glucose. Symbols are: (),
nephropath 1; (), nephropath 2.
3.5 increase of ALR2 mRNA in contrast to those with to the 5ALR2 genotype that those nephropaths with
the highest ALR2 expression and the Z–2/X genotypethe Z
2/Y (where Y is not Z–2) genotype, who only
had a 2.9  0.2 increase in ALR2 mRNA (P  0.04). did not necessarily have the most SORD mRNA. In
the uncomplicated group, there was no correlation withSurprisingly, those nephropaths with the Z–2/Z
2 geno-
type had the lowest increase in ALR2 mRNA (1.3  5ALR2 genotype, as they did not increase their expres-
sion of ALR2 with hyperglycemia (data not shown). Four0.3). Indeed, when the increase in the Z–2/X genotype
group is compared with the Z
2/Y and the Z–2/Z
2 as of the 11 uncomplicated patients had the Z–2/X geno-
type. Six had the Z
2/Y genotype, and the last subjecta whole, this difference was significant (P 0.007). Also,
it is clear from the SORD mRNA results with respect had the X/Y genotype.
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Table 3. Aldose reductase and SORD mRNA levels with respect cotransporter, when the cells are exposed to high glucose
to 5ALR2 genotype in patients with diabetic nephropathy
[26]. This effect can be reversed by the addition of aldose
ALR2 SORD ARL2/SORD ratio reductase inhibitors. The increase in SORD mRNA
found in the PBMCs of the patients with nephropathyZ2/X (N  10) 8.43.5ab 2.140.8 4.41.5
Z
2/Y (N  6) 2.90.2 2.91.0 1.90.2 is in contrast to the response seen in rat inner medullary
Z2/Z
2 (N  4) 1.30.3 1.650.1 0.60.07 collecting duct cells exposed to high osmolarity [27]. InX/Y (N  9) 4.31.0 1.60.3 3.81.2
this model using a reverse transcription-PCR strategy, a
The results are expressed as mean fold increases of the PBMC exposed to
fourfold increase in the level of aldose reductase mRNAsevere hyperglycemic compared with those cultured under normal conditions 
standard error. is found within 24 hours of exposure to high osmolarity,
X  any allele other than Z
2; Y  any allele other than Z2.
but no difference in the expression of SORD is seen. Ita vs. ALR2 Z
2/Y, P  0.04
b vs. ALR2 Z
2/Y plus Z2/Z
2, P  0.007 is also possible that the response to d-glucose in the
nephropaths is due to the underlying renal dysfunction
in these patients. This response may also occur in patients
with nondiabetic renal disease.DISCUSSION
While nephropaths showed an increase in expression ofThis study shows, to our knowledge for the first time,
the ALR2 gene with increasing concentration of d-glucose,that the expression of both the ALR2 and SORD genes
the degree of the response varied. This correlated with theis induced by d-glucose in PBMCs in those patients with
5ALR2 genotype with those possessing the Z–2/X typenephropathy. This response was specific for d-glucose
having the greatest response. An examination of bothand was not due to differences in osmolarity, as demon-
the ALR2 and SORD mRNA expression suggests thatstrated by the lack of response to l-glucose and mannitol.
there may be at least two profiles of flux through theHowever, the major finding from this study is the quite
polyol pathway under hyperglycemic conditions. Thosestriking and unexpected lack of a response of the ALR2
nephropaths with the Z–2/X genotype had the greatestgene to d-glucose in the PBMCs of the uncomplicated
increase in ALR2 mRNA, but only a modest increasepatients (no microvascular complications after 20 years
in SORD mRNA. Consequently, it is possible that induration of type 1 diabetes) as well as the normal controls.
these individuals there is an accumulation of sorbitol inThe reasons for this disparity are unclear at the present
the cell. In contrast, those nephropaths with the Z
2/Ytime, but obviously have major implications for under-
as well as the Z–2/Z
2 genotype had a similar increasestanding and possibly predicting diabetic nephropathy
of both ALR2 and SORD mRNA. Sorbitol would notand other microvascular complications of diabetes. It is
be expected to accumulate in these cells. Instead, thepossible that these differences can be accounted for by
exaggerated flux through the entire polyol pathwaythe expression and function of glucose transporters be-
would be important, and this would give rise to increasedtween those with and without nephropathy. We and others
levels of fructose and perhaps depletion of the cofactorshave recently shown that polymorphisms in GLUT1, the
NADPH and NAD
. It is also apparent that the presencemajor facilitative glucose transporter in insulin-non-
of the Z
2 allele is dominant over the Z–2 allele. Thisresponsible tissues, such as the retinal epithelial cells and
is somewhat surprising and may be related to the affinityglomeruli, is associated with susceptibility to diabetic
of the transcription factors for the regulatory responsenephropathy in patients with type 1 and type 2 diabetes
elements, which is perhaps modified by the presence of[24, 25]. This association is related to the 5ALR geno-
additional CA dinucleotide repeats. It has already beentype. Therefore, the availability of glucose as a substrate
shown that the Z–4 allele can modify the efficiency ofmay be an important factor, although this may not neces-
transcription in luciferase gene reporter assays [22].sarily be related to glycemic control. Indeed, the nephro-
In conclusion, this is the first description of mRNApaths and uncomplicated group had similar HbA1c re- profiles for genes coding for enzymes of an entire meta-sults. It is possible that the uncomplicated group and
bolic pathway. We have found striking differences in thenormal controls did respond to d-glucose, but this was
expression profile of ALR2 of patients with nephropathybefore the five-day end point by which time the response
compared with those without and the normal controls.may have been down-regulated. Natural cellular inhibi-
The response to uptake and disposal of d-glucose maytors of the polyol pathway have not been found, and it
be quite different between these groups of patients andis assumed that the flux through the pathway is simply
provides a novel insight into the role of the polyol path-regulated by the concentration of the substrate and co-
way in the pathogenesis of diabetic nephropathy.factors. It remains unclear why high concentrations of
d-glucose should fail to stimulate the expression of the
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